Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
European Journal of Cancer, 06/12/2012
Clinical Article
Meulenbeld HJ et al. – The addition of the third generation bisphosphonate, risedronate, in the setting of effective first line docetaxel based chemotherapy did not increase efficacy, as indicated by the lack of improvement in time to progression (TTP), overall survival (OS), PSA– and pain response.



